Pahlavani Naseh, Jafari Mostafa, Sadeghi Omid, Rezaei Masoud, Rasad Hamid, Rahdar Hossein Ali, Entezari Mohammad Hasan
Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Food Security Research Center and Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
F1000Res. 2014 Dec 12;3:306. doi: 10.12688/f1000research.5877.2. eCollection 2014.
The effect of L-arginine on risk factors of cardiovascular diseases (CVD) has mostly focused on western countries. Since cardiovascular diseases is the second cause of death in Iran and, as far as we are aware, there have been no studies about the effect of L-arginine on CVD risk factors, the aim of this trial was to assess the effects of L-arginine supplementation on CVD risk factors in healthy men. The purpose of this study was to evaluate the effect of low-dose L-arginine supplementation on CVD risk factors (lipid profile, blood sugar and blood pressure) in Iranian healthy men. We conducted a double-blind randomized controlled trial in 56 patients selected from sport clubs at the Isfahan University of Medical Science between November 2013 and December 2013. Healthy men received L-arginine supplementation (2000 mg daily) in the intervention group or placebo (2000 mg maltodextrin daily) in the control group for 45 days. The primary outcome measures were we measured the levels of fasting blood sugar, blood pressure and lipid profile including triglyceride (TG), cholesterol, LDL and HDL in healthy subjects. It was hypothesized that these measures would be significantly improved in those receiving L-arginine supplementation. at the beginning and end of the study. In this trial, we had complete data for 52 healthy participants with mean age of 20.85±4.29 years. At the end of study, fasting blood sugar (P=0.001) and lipid profile (triglycerideTG (P<0.001), cholesterol (P<0.001), LDL (P=0.04), HDL (P=0.015)) decreased in the L-arginine group but we found no significant change in the placebo group. In addition, the reduction of fasting blood sugar and lipid profile in L-arginine was significant compared with placebo group. No significant changes were found about systolic (P=0.81) and diastolic blood pressure either in L-arginine or placebo group. (P=0.532). : The use of L-arginine significantly improved outcomes compared to placebo.
L-精氨酸对心血管疾病（CVD）危险因素的影响大多集中在西方国家。由于心血管疾病是伊朗的第二大致死原因，且据我们所知，尚无关于L-精氨酸对CVD危险因素影响的研究，因此本试验的目的是评估补充L-精氨酸对健康男性CVD危险因素的影响。本研究的目的是评估低剂量补充L-精氨酸对伊朗健康男性CVD危险因素（血脂谱、血糖和血压）的影响。2013年11月至2013年12月期间，我们在伊斯法罕医科大学体育俱乐部挑选的56名患者中进行了一项双盲随机对照试验。干预组的健康男性接受L-精氨酸补充剂（每日2000毫克），对照组接受安慰剂（每日2000毫克麦芽糊精），持续45天。主要结局指标是我们测量了健康受试者的空腹血糖、血压和血脂谱水平，包括甘油三酯（TG）、胆固醇、低密度脂蛋白和高密度脂蛋白。据推测，接受L-精氨酸补充剂的受试者的这些指标将得到显著改善。在研究开始和结束时。在本试验中，我们获得了52名健康参与者的完整数据，平均年龄为20.85±4.29岁。研究结束时，L-精氨酸组的空腹血糖（P=0.001）和血脂谱（甘油三酯TG（P<0.001）、胆固醇（P<0.001）、低密度脂蛋白（P=0.04）、高密度脂蛋白（P=0.015））降低，但我们发现安慰剂组无显著变化。此外，与安慰剂组相比，L-精氨酸组空腹血糖和血脂谱的降低具有显著性。L-精氨酸组和安慰剂组的收缩压（P=0.81）和舒张压均未发现显著变化。（P=0.532）：与安慰剂相比，使用L-精氨酸显著改善了结局。
